MK-677 · Research brief

MK-677 for Lean Bulk — Growth Hormone Pathway Explained

Real Peptides Research TeamEditorial

Updated September 24, 202611 min read

46 WORDS

Short answer

Key takeaways

MK-677 increases mean 24-hour growth hormone levels by 60–89% through ghrelin receptor agonism without suppressing endogenous testosterone or requiring injections.
Effective lean bulk dosing ranges from 12.5mg to 25mg daily, with 25mg producing near-maximal GH stimulation and higher doses offering minimal additional benefit while increasing side effects.
MK-677 elevates appetite significantly within 30–60 minutes of administration due to ghrelin receptor activation. This can support high-calorie intake adherence during structured surplus or lead to uncontrolled eating if not managed.
Evening dosing aligns with natural nocturnal GH pulses and may enhance slow-wave sleep duration, while morning or pre-workout dosing capitalizes on appetite stimulation for post-training nutrition.
Response variability is substantial. Lean individuals under 12% body fat typically respond more favorably than those with higher adiposity due to reduced insulin resistance and better IGF-1 signalling efficiency.
MK-677 modestly elevates fasting blood glucose (5–10 mg/dL average) through GH's counter-regulatory effects on insulin. Baseline glucose monitoring is essential for protocols longer than 12 weeks.

Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that MK-677 (ibutamoren) administration increased mean 24-hour growth hormone levels by 89% and IGF-1 concentrations by 62% in healthy adults. Without requiring injections and without suppressing endogenous testosterone production. That's not a typical SARM profile. That's a selective ghrelin receptor agonist that mimics the body's natural hunger-signalling pathway to trigger pulsatile GH release from the pituitary gland. The distinction matters because MK-677 for lean bulk isn't a direct anabolic compound. It's a biological signal amplifier that creates the hormonal environment where lean tissue accrual becomes mechanistically easier during structured caloric surplus.

Our team has worked with researchers evaluating growth hormone secretagogues for body recomposition protocols. The gap between using MK-677 correctly and wasting it comes down to three factors most guides gloss over: dose timing relative to natural GH pulses, caloric structure during the protocol, and baseline sleep architecture.

How does MK-677 support lean bulking without suppressing natural testosterone production?

MK-677 for lean bulk works by binding to ghrelin receptors (GHSR1a) in the hypothalamus and pituitary gland, stimulating growth hormone secretion through the same pathway your body uses when fasting signals energy depletion. This mechanism increases both GH and IGF-1 levels by 40–90% depending on dose and individual response, which enhances protein synthesis, nitrogen retention, and lipolysis during caloric surplus. All without interacting with androgen receptors or suppressing the hypothalamic-pituitary-gonadal axis that regulates testosterone.

The standard definition calls MK-677 a selective ghrelin receptor agonist. But that label obscures what actually happens at the cellular level. Unlike exogenous GH injections that flood the system with supra-physiological levels, MK-677 mimics the body's natural ghrelin signalling to produce pulsatile GH release that maintains circadian rhythm alignment. The practical result: you get elevated GH without the feedback suppression that shuts down endogenous production or the side-effect profile associated with direct GH administration. This article covers the receptor mechanism that makes MK-677 effective for lean bulk, the dosage ranges clinical trials support, and the timing strategies that optimize nitrogen retention without triggering excessive water retention or insulin resistance.

What MK-677 Actually Does to Growth Hormone Secretion

Growth hormone isn't released continuously. It pulses. The pituitary gland secretes GH in bursts approximately 6–8 times per day, with the largest pulse occurring 60–90 minutes into deep (Stage 3) sleep. Under normal conditions, ghrelin. The hunger hormone produced primarily in the stomach. Signals the hypothalamus that energy stores are depleted, which triggers somatotroph cells in the anterior pituitary to release GH. MK-677 binds to the same ghrelin receptors (growth hormone secretagogue receptor type 1a, or GHSR1a) without requiring caloric restriction or fasting, effectively telling your pituitary to release GH as if you were in an energy-deficit state even when you're eating at caloric surplus.

Clinical studies show MK-677 increases mean 24-hour GH levels by 60–89% at doses ranging from 10mg to 25mg daily. That elevation isn't constant. MK-677 preserves the natural pulsatile pattern rather than creating a steady-state flood. The downstream effect is increased hepatic production of insulin-like growth factor 1 (IGF-1), which mediates most of GH's anabolic effects: enhanced amino acid uptake into muscle cells, upregulation of protein synthesis pathways (mTOR activation), and preferential fat oxidation for energy rather than glucose or amino acids. For lean bulking, this creates a nutrient-partitioning advantage. More of your caloric surplus gets directed toward muscle tissue synthesis rather than adipose storage.

The catch: elevated GH also increases appetite through ghrelin receptor activation. MK-677 users consistently report significant hunger increases within 30–60 minutes of administration, which is mechanistically expected given the receptor target. For a lean bulk protocol where you're already in structured caloric surplus, this can either support adherence to high-calorie intake goals or lead to uncontrolled overeating if not managed with meal timing discipline. Additionally, MK-677 elevates fasting blood glucose modestly (5–10 mg/dL on average) due to GH's counter-regulatory effects on insulin. Chronic hyperglycemia risk exists if baseline glucose control is poor or if the protocol runs beyond 12–16 weeks without monitoring.

Dosage, Timing, and Response Variability for Lean Bulk Goals

The published literature on MK-677 spans doses from 10mg to 50mg daily, but the response curve isn't linear. A study published in Growth Hormone & IGF Research found that 25mg daily produced near-maximal GH stimulation, with 50mg daily offering minimal additional benefit while increasing side effects (edema, joint stiffness, blood glucose elevation). For lean bulk purposes, the effective range is 12.5mg to 25mg daily. Higher doses don't proportionally increase anabolism and carry greater metabolic burden.

Timing matters because of MK-677's half-life (approximately 24 hours) and the natural circadian rhythm of GH release. Most users administer MK-677 once daily either in the evening (to amplify the natural nocturnal GH pulse) or pre-workout (to capitalize on appetite stimulation for post-training nutrition). Evening dosing aligns with the body's endogenous GH peak during slow-wave sleep and may enhance sleep quality through increased Stage 3/4 sleep duration. A documented effect in older adults but less pronounced in younger populations with already-normal sleep architecture. Morning or pre-workout dosing places the appetite surge at a time when high-calorie intake is strategically useful, but may blunt the natural evening GH pulse if receptor desensitization occurs.

Response variability is significant. Baseline GH and IGF-1 status, body composition, training age, and genetic polymorphisms in GHSR1a receptors all influence how much benefit an individual extracts from MK-677. Younger users (under 30) with naturally higher GH production may see smaller absolute gains than older users whose endogenous GH has declined. Our experience working with researchers in peptide protocols shows consistent patterns: lean individuals with low body fat (under 12%) respond more favorably to GH elevation for muscle accrual than individuals carrying significant adipose tissue, where insulin resistance can blunt IGF-1 signalling. Blood work. Specifically fasting IGF-1 and glucose. Provides objective feedback on whether the protocol is working and whether metabolic side effects are emerging.

MK-677 for Lean Bulk: Growth Secretagogue Comparison

Compound	Mechanism	Typical GH Increase	Half-Life	Suppression Risk	Administration
MK-677 (Ibutamoren)	Ghrelin receptor agonist (GHSR1a)	60–89% mean 24-hour GH elevation	~24 hours	No testosterone suppression. Does not affect HPG axis	Oral, once daily
GHRP-2	Growth hormone releasing peptide (synthetic ghrelin analog)	200–300% acute GH pulse	~30 minutes	No suppression (peptide class)	Subcutaneous injection, 2–3x daily
CJC-1295 (DAC)	GHRH analog (growth hormone releasing hormone)	200–400% sustained GH elevation over 7–14 days	6–8 days	No suppression (peptide class)	Subcutaneous injection, weekly
Exogenous GH (Somatropin)	Direct recombinant human growth hormone	Variable (dose-dependent, supra-physiological)	3–4 hours	Suppresses endogenous GH production via negative feedback	Subcutaneous injection, daily
Bottom Line / Professional Assessment	MK-677 offers the convenience of oral dosing without injections and preserves pulsatile GH release without suppressing endogenous production. Making it the most practical option for lean bulk protocols where compliance and natural hormone preservation matter. GHRP-2 and CJC-1295 produce higher acute GH spikes but require injections and don't offer oral bioavailability. Exogenous GH delivers the highest raw GH levels but shuts down natural production and carries the greatest metabolic and legal risk.

MK-677 sits in a unique position: it's not as potent as direct GH or peptide stacks, but it requires no injections, preserves natural hormone rhythms, and avoids the regulatory complexity of controlled substances. For a 12–16 week lean bulk where the goal is gradual muscle accrual with minimal fat gain, MK-677 at 12.5–25mg daily provides a meaningful GH and IGF-1 boost without the logistical burden or metabolic shutdown associated with injectable alternatives. That said, it's not a substitute for structured training and caloric surplus. It's an amplifier, not a replacement.

What If: MK-677 for Lean Bulk Scenarios

What If I Don't Feel Increased Appetite After Starting MK-677?

Check your product source and batch purity first. Underdosed or degraded product is the most common explanation for absent appetite stimulation, which is one of MK-677's most consistent acute effects. Legitimate MK-677 at 12.5mg or higher produces noticeable hunger within 30–90 minutes in the vast majority of users due to direct ghrelin receptor activation. If appetite remains unchanged after three days at 25mg, the compound is likely not active. Alternatively, individuals with chronically elevated baseline ghrelin (common in chronic dieters or those with poor sleep quality) may experience blunted subjective appetite response even when GH elevation is occurring. Blood work measuring IGF-1 levels before and three weeks into the protocol confirms whether the compound is working biologically regardless of subjective hunger.

What If I Experience Significant Water Retention on MK-677?

Water retention (edema) is a documented side effect of elevated growth hormone levels, caused by increased aldosterone secretion and sodium retention in response to GH-mediated changes in renal handling. This typically manifests as mild hand or ankle swelling and can add 2–5 pounds of scale weight within the first two weeks. The retention is extracellular, not intramuscular, meaning it's cosmetically noticeable but doesn't contribute to lean tissue gain. Reduce sodium intake to 2,000–2,500mg daily, ensure adequate potassium intake (3,500–4,500mg), and consider spacing carbohydrate intake evenly throughout the day rather than loading post-workout. Carbohydrate-induced insulin spikes compound water retention when GH is elevated. If edema persists beyond three weeks or worsens, discontinue MK-677 and evaluate kidney function through blood work. Chronic fluid retention suggests impaired renal clearance.

What If My Fasting Blood Glucose Increases on MK-677?

Growth hormone has counter-regulatory effects on insulin, meaning it promotes glucose release from the liver and reduces peripheral glucose uptake. A survival mechanism designed to preserve blood sugar during fasting or stress. MK-677 users commonly see fasting glucose rise by 5–10 mg/dL, which is metabolically insignificant if baseline glucose control is normal (fasting glucose under 100 mg/dL). However, individuals with pre-existing insulin resistance, prediabetes, or poor glycemic control may see larger increases that edge into clinically concerning territory (fasting glucose above 110 mg/dL). Monitor fasting glucose weekly during the first month. If levels exceed 110 mg/dL or HbA1c rises above 5.7%, either reduce MK-677 dose to 10–12.5mg daily or discontinue the protocol entirely. Combining MK-677 with metformin (500–1,000mg daily) or berberine (1,500mg daily split into three doses) can mitigate glucose elevation, but this introduces additional pharmacological complexity.

The Practical Truth About MK-677 for Lean Bulk

Here's the honest answer: MK-677 won't add 15 pounds of muscle in 12 weeks. Not even close. The marketing around growth hormone secretagogues overstates their direct anabolic capacity. What MK-677 actually delivers is a 15–25% increase in circulating IGF-1 and a modest improvement in nitrogen retention that translates to an additional 1–2 pounds of lean tissue over a structured 12-week lean bulk compared to training and nutrition alone. Assuming caloric surplus, progressive overload, and adequate protein intake (1.6–2.2g per kg body weight daily) are already dialed in. The compound works, but it's not a miracle. It's an incremental advantage.

The real value proposition isn't raw muscle gain. It's recovery enhancement and nutrient partitioning. Elevated GH improves collagen synthesis, which supports tendon and ligament repair during high-volume training phases. It enhances sleep quality by increasing slow-wave sleep duration, which is when the majority of tissue repair and protein synthesis occur. And it shifts substrate utilization toward fat oxidation rather than glucose or amino acids, meaning more of your caloric surplus gets directed toward muscle rather than fat storage. Those are meaningful benefits for someone running a structured lean bulk, but they're conditional on doing everything else right.

If your training isn't progressive, your protein intake is suboptimal, or your caloric surplus is too aggressive, MK-677 won't save the protocol. It amplifies what's already working. It doesn't fix what's broken. The peptide research community has learned this the hard way: growth hormone elevation without structured anabolic stimulus and nutritional precision produces minimal results. You can learn more about high-purity research peptides and see how quality sourcing impacts biological outcomes at Real Peptides, where small-batch synthesis and exact amino-acid sequencing ensure consistency across protocols.

Another honest point: the appetite increase is not subtle. For individuals who struggle to eat enough calories during a bulk, MK-677's ghrelin agonism is a strategic asset. For individuals who already overeat or have poor hunger regulation, it becomes a liability. If you can't stick to structured meal timing and portion control, the compound will drive uncontrolled caloric intake and fat gain rather than lean tissue accrual. The biological mechanism doesn't distinguish between productive surplus and reckless overeating. It just amplifies hunger signalling. That's not a flaw in the compound; it's a reminder that pharmacological tools require disciplined application.

MK-677 for lean bulk works best as a 12–16 week protocol during a structured mesocycle where training volume is high, recovery demand is elevated, and caloric surplus is moderate (200–300 calories above maintenance). It's not a standalone solution, and it's not appropriate for cutting phases where appetite suppression is the goal. Used correctly, it adds a measurable but modest edge. Used carelessly, it adds water weight, disrupts glucose control, and delivers minimal return on investment.

If the compound interests you from a research perspective. Whether for lean bulk protocols or other applications like recovery enhancement or metabolic health. Explore our Body Recomp Bundle or Muscle Building Recovery Bundle to see how high-purity peptides integrate into structured protocols. Small-batch synthesis ensures every vial delivers consistent potency, which matters when evaluating biological response across multi-week studies.

The question isn't whether MK-677 works. It does. The question is whether the incremental benefit justifies the cost, the appetite management requirement, and the glucose monitoring burden. For someone running a meticulous lean bulk with room in the budget, the answer is often yes. For someone hoping it'll compensate for suboptimal training or nutrition, the answer is definitively no.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

MK-677 stimulates your body's endogenous growth hormone production through ghrelin receptor agonism, preserving the natural pulsatile release pattern that occurs 6–8 times daily and maintaining circadian alignment with your sleep cycle. Exogenous GH (somatropin) delivers direct recombinant human growth hormone at supra-physiological doses that override natural production, which suppresses endogenous GH secretion through negative feedback and creates a steady-state elevation rather than pulses. MK-677 increases mean 24-hour GH by 60–89% without shutting down your own production, while exogenous GH can elevate levels 300–500% but causes complete feedback suppression that persists for weeks after discontinuation. The practical difference: MK-677 preserves your natural hormone function and requires no injections, while exogenous GH delivers higher raw GH levels but at the cost of endogenous shutdown and significantly greater metabolic side-effect risk.

MK-677 can technically be used during a caloric deficit, but the appetite stimulation it produces through ghrelin receptor activation makes adherence to restricted calorie intake significantly harder for most users. Growth hormone elevation does support fat oxidation and nitrogen retention during dieting, which theoretically aids muscle preservation, but the practical reality is that managing intense hunger while trying to maintain a deficit often outweighs the anti-catabolic benefit. MK-677 for lean bulk works best in caloric surplus where the appetite increase supports high-calorie intake goals rather than fighting against them. If fat loss is the primary goal, compounds that don't stimulate appetite — or peptides like CJC-1295 that elevate GH without ghrelin receptor involvement — are more practical choices.

Baseline fasting glucose, HbA1c, and IGF-1 levels should be measured before starting MK-677, with follow-up testing at 3–4 weeks and again at 8–12 weeks if the protocol continues beyond that. Growth hormone's counter-regulatory effects on insulin can elevate fasting blood glucose by 5–10 mg/dL in most users, but individuals with pre-existing insulin resistance or poor glycemic control may see larger increases that become clinically significant (fasting glucose above 110 mg/dL or HbA1c above 5.7%). IGF-1 measurement confirms whether the compound is biologically active — legitimate MK-677 at 20–25mg daily should increase IGF-1 by 40–80 ng/mL from baseline within three weeks. If IGF-1 doesn't rise, the product is either underdosed or degraded. Thyroid function (TSH, free T3, free T4) is optional but useful if fatigue or metabolic changes occur, as chronic GH elevation can slightly suppress thyroid hormone conversion in some individuals.

No — MK-677 does not suppress the hypothalamic-pituitary-gonadal (HPG) axis that regulates testosterone production, so there is no suppression rebound requiring PCT. Unlike SARMs or anabolic steroids that bind to androgen receptors and trigger negative feedback that shuts down endogenous testosterone synthesis, MK-677 works exclusively through ghrelin receptors (GHSR1a) in the hypothalamus and pituitary to stimulate growth hormone release. Your natural testosterone production remains unaffected throughout the protocol. When you discontinue MK-677, GH and IGF-1 levels return to baseline within 5–7 days (the compound's half-life is approximately 24 hours, so clearance is relatively fast), but there is no hormonal crash or recovery period required. The only adjustment needed is managing the return of normal appetite once ghrelin receptor stimulation ceases.

Most structured lean bulk protocols using MK-677 run 12–16 weeks, aligning with a typical hypertrophy mesocycle where training volume is high and caloric surplus is maintained. Longer continuous use (beyond 16–20 weeks) increases the risk of insulin resistance development, glucose dysregulation, and diminishing returns as receptor sensitivity may decline. Clinical studies have evaluated MK-677 for up to 24 months in elderly populations for bone density and muscle mass preservation, but those protocols used lower doses (10–12.5mg daily) and were medically supervised with regular metabolic monitoring. For lean bulk purposes at 20–25mg daily, a 12-week-on, 4-week-off cycling structure balances benefit and metabolic burden. Blood glucose monitoring every 4 weeks during active use ensures early detection of any adverse metabolic shifts.

Evening dosing (60–90 minutes before bed) aligns with the body's natural nocturnal growth hormone pulse that occurs during slow-wave sleep and may enhance sleep quality by increasing Stage 3/4 sleep duration, which is when most tissue repair and protein synthesis occur. Morning or pre-workout dosing capitalizes on the appetite surge for strategic high-calorie intake post-training but may blunt the natural evening GH pulse if receptor desensitization occurs from earlier stimulation. Most users find evening dosing more practical for lean bulk protocols because it supports both GH optimization and recovery, while the appetite increase can be managed with a structured pre-bed meal rather than causing uncontrolled daytime eating. Individual response varies — experiment with both timing windows during the first week to determine which produces better subjective recovery and appetite alignment with your meal schedule.

Yes — MK-677 is commonly stacked with SARMs (such as LGD-4033 or RAD-140) or other peptides (such as BPC-157 for recovery support) in research protocols aimed at maximizing lean tissue accrual and recovery during structured surplus phases. The rationale is that MK-677 provides systemic GH and IGF-1 elevation while SARMs deliver direct androgen receptor activation in muscle tissue, creating synergistic anabolic signalling through complementary pathways. However, stacking compounds increases metabolic complexity, side-effect risk, and the difficulty of isolating which compound is responsible for any adverse response. For first-time users, running MK-677 as a standalone compound for 12 weeks allows clear assessment of its individual effect before introducing additional variables. If stacking, baseline blood work (testosterone, liver enzymes, lipids, glucose, IGF-1) becomes non-negotiable, and mid-protocol monitoring at 4–6 weeks is essential to detect suppression or metabolic dysfunction early.

Growth hormone elevation increases collagen synthesis and extracellular matrix remodelling, which can cause temporary joint stiffness or discomfort as connective tissues adapt — particularly in individuals over 30 whose baseline GH production has declined and whose joints aren't accustomed to accelerated collagen turnover. This is distinct from the joint lubrication and pain relief that GH provides long-term; the stiffness is an early-phase adaptation response. Additionally, water retention (edema) caused by GH-induced sodium retention can create a sensation of tightness around joints and tendons. Most users find this resolves within 2–3 weeks as the body acclimates. Reducing sodium intake, ensuring adequate hydration (3–4 litres daily), and incorporating light mobility work or foam rolling can mitigate discomfort. If joint pain worsens or persists beyond three weeks, discontinue MK-677 and evaluate for underlying inflammatory conditions that elevated GH may be exacerbating.

MK-677 is not approved by the FDA for human consumption and is classified as a research chemical rather than a prescription medication or dietary supplement. It is legal to purchase for research purposes in most jurisdictions, but it is explicitly banned by the World Anti-Doping Agency (WADA) for competitive athletes, and its sale for human consumption violates FDA regulations in the United States. Reputable suppliers sell MK-677 labelled 'for research use only' or 'not for human consumption' to comply with regulatory frameworks. Possession for personal research is generally not prosecuted, but selling or distributing MK-677 as a dietary supplement or performance-enhancing drug can result in legal consequences. Athletes subject to WADA testing should avoid MK-677 entirely — it is detectable in urine and blood tests and will result in sanctions if found.

Muscle tissue accrued during an MK-677-supported lean bulk is retained post-protocol as long as training volume, progressive overload, and adequate protein intake are maintained — the lean tissue you built is structurally real, not water weight or transient glycogen expansion. However, the elevated GH and IGF-1 environment that supported accelerated recovery and nitrogen retention will return to baseline within 5–7 days after discontinuation, meaning recovery capacity and protein synthesis efficiency will decrease back to pre-protocol levels. You won't lose muscle, but the rate at which you can continue building new tissue will slow to what your natural GH production supports. Water retention (typically 2–5 pounds) will also dissipate within the first week off MK-677 as aldosterone levels normalize and sodium balance resets, which may create the illusion of muscle loss on the scale despite lean tissue remaining unchanged.

Yes — MK-677 increases slow-wave sleep (Stage 3 and 4 NREM sleep) duration by approximately 20–50% in clinical studies, which is the sleep phase during which the majority of growth hormone secretion, protein synthesis, and tissue repair occur. Enhanced sleep architecture directly contributes to lean bulk results because muscle protein synthesis rates are highest during deep sleep, and inadequate slow-wave sleep is one of the primary factors limiting recovery in high-volume training phases. Subjectively, users report falling asleep faster, experiencing fewer nocturnal awakenings, and waking more refreshed. This effect is more pronounced in individuals over 30 whose natural GH production and slow-wave sleep duration have declined with age. Younger users (under 25) with already-optimal sleep architecture may notice less dramatic improvement but still benefit from the GH pulse amplification that occurs during the extended deep sleep window MK-677 creates.

The most common mistake is failing to structure caloric intake properly — MK-677 amplifies appetite significantly, and users either undershoot their surplus out of fear of fat gain or overshoot recklessly and gain excessive adipose tissue. A controlled surplus of 200–300 calories above maintenance, with protein at 1.6–2.2g per kg body weight, is required to capitalize on the elevated GH and IGF-1 environment without wasting the compound's nutrient-partitioning advantage. Second mistake: neglecting glucose monitoring, especially in individuals with pre-existing insulin resistance or poor baseline glycemic control — unchecked fasting glucose elevation compounds metabolic dysfunction and reduces IGF-1 signalling efficiency. Third mistake: running the protocol without progressive overload in training — MK-677 enhances recovery and creates a more anabolic hormonal environment, but it doesn't build muscle without mechanical tension stimulus. If training volume or intensity doesn't increase to challenge the enhanced recovery capacity, the compound delivers minimal results.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA